Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4

BACKGROUND: The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation does not exclude the existence of neoantigen-specific T cells...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Bulk, Jitske, Verdegaal, Els M. E., Ruano, Dina, Ijsselsteijn, Marieke E., Visser, Marten, van der Breggen, Ruud, Duhen, Thomas, van der Ploeg, Manon, de Vries, Natasja L., Oosting, Jan, Peeters, Koen C. M. J., Weinberg, Andrew D., Farina-Sarasqueta, Arantza, van der Burg, Sjoerd H., de Miranda, Noel F. C. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938004/
https://www.ncbi.nlm.nih.gov/pubmed/31888734
http://dx.doi.org/10.1186/s13073-019-0697-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938004/
https://www.ncbi.nlm.nih.gov/pubmed/31888734
http://dx.doi.org/10.1186/s13073-019-0697-8

Ejemplares similares